Metrics as of 10/16/2026, 08:38 AM (Berlin time), refresh in progress.
Adaptive Biotechnologies Stock
Adaptive Biotechnologies Corporation
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Chad Robins
- Employees
- 624
- Market cap
- $4.1 B
- IPO
- 27/06/2019
Adaptive Biotechnologies Corporation is a healthcare company in the biotechnology sector headquartered in Seattle, USA. Founded in 2009, the company focuses on pioneering an immune medicine platform engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. Its technological…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Adaptive Biotechnologies stock: price history
1D
-0.2%
1W
-2.0%
1M
-4.1%
6M
+81.7%
YTD
+57.5%
1Y
+49.5%
2Y
+414.7%
5Y
-23.6%
10Y
–
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~33% stronger price swings than usual
Adaptive Biotechnologies stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Very robust business model with strong megatrend tailwind: wide moat, strong pricing power, predictable revenue.
2 more assignments (Enabler/Second row) Pro-only.
Adaptive Biotechnologies Corporation operates a specialized immune medicine platform aimed at precisely diagnosing and treating diseases. The company offers solutions such as the ImmunoSEQ system for research as well as clinical diagnostics like clonoSEQ for monitoring cancer. Revenues are generated through sequencing services, research support, and regulatory milestones in product development. Through strategic partnerships with Genentech and Microsoft, the company works on advanced diagnostic tools and T-cell therapies. The portfolio addresses various medical areas from cancer to infectious diseases and serves both life science research and clinical diagnostics.
- Revenue model
- Mixed
- Recurring revenue
- High
- Pricing power
- Strong
- Moat
- Narrow
- Moat type
- Brand / IP
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Adaptive Biotechnologies
Analyst assessment of Adaptive Biotechnologies
PRICE TARGET LOW
US$27.00
CONSENSUS
US$31.58
MEDIAN
US$33.00
PRICE TARGET HIGH
US$35.00
0
STRONG BUY
11
BUY
4
HOLD
2
SELL
0
STRONG SELL
17
TOTAL · Buy
As of: 13/10/2026
Adaptive Biotechnologies stock metrics
P/E
-62.79
P/B
28.23
EV/EBITDA
-270.84
RETURN ON EQUITY
-27.8%
NET MARGIN
-55.6%
DEBT/EQUITY
2.87
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
97.0%
FLOAT SHARES
154,873,714
AVG. DAILY VOLUME (30D)
2,350,617
Insider transactions (SEC)
RUBINSTEIN JULIE
RUBINSTEIN JULIE
RUBINSTEIN JULIE
RUBINSTEIN JULIE
RUBINSTEIN JULIE
Institutional holders
Comparable stocks
Frequently asked questions about Adaptive Biotechnologies stock
What does Adaptive Biotechnologies do?
Adaptive Biotechnologies Corporation is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Chad Robins, the company employs around 624 people.
The IPO was on 27/06/2019; the stock trades on NASDAQ under the ticker ADPT.
What do analysts say about Adaptive Biotechnologies stock?
17 analysts rate the stock, the consensus is Buy (as of 13/10/2026).
The average price target is US$31.58, ranging from US$27.00 to US$35.00, with a median of US$33.00.
This is an external assessment, not a statement by Market Jury.
When does Adaptive Biotechnologies report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly 33% stronger than usual.
Does Adaptive Biotechnologies pay a dividend?
No, Adaptive Biotechnologies currently does not pay a dividend.
Which stocks are comparable to Adaptive Biotechnologies?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Adaptive Biotechnologies stock analyzed?
Clicking "Analyze stock" lets five strategies assess Adaptive Biotechnologies against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.